Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients [0.03%]
初始应用非侵入性心脏检查及其与后续医疗资源使用情况的相关性：对疑似第一型心肌梗塞患者的回顾性分析
Dana Villines,Wm Thomas Summerfelt,James R Spalding et al.
Dana Villines et al.
Background: Clinical guidelines provide clinicians with substantial discretion in the use of noninvasive cardiac testing for patients with suspected coronary artery disease. Repeat testing, frequent emergency department (...
Using a Discrete-Choice Experiment to Estimate the Preferences of Clinical Practitioners for a Novel Non-invasive Device for Diagnosis of Peripheral Arterial Disease in Primary Care [0.03%]
采用离散选择试验估算临床从业人员对新型外周动脉疾病诊断设备的偏好
Yemi Oluboyede,Laura Ternent,Luke Vale et al.
Yemi Oluboyede et al.
Background: Peripheral arterial disease (PAD) is a common condition that causes significant morbidity and reduced life expectancy, and can have a serious economic impact. It is often underdiagnosed in primary care, partia...
Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017 [0.03%]
2012至2017年爱尔兰罕见病药物卫生技术评估分析
Cara Usher,Laura McCullagh,Lesley Tilson et al.
Cara Usher et al.
Background: In Ireland, health technology assessment (HTA) submissions for orphan drugs or drugs for rare diseases have increased in recent years but have not been explicitly analysed. All evaluations are conducted by the...
Bishal Mohindru,David Turner,Tracey Sach et al.
Bishal Mohindru et al.
Introduction: Cystic fibrosis (CF) is a life-limiting, hereditable condition, with the highest prevalence in Europe. CF treatments have led to improvements in clinical symptoms, disease management and decelerated disease ...
Benedikt Schoser,Andreas Hahn,Emma James et al.
Benedikt Schoser et al.
Background: Pompe disease is a rare, severe neuromuscular disease with high mortality and substantial clinical and humanistic burden. However, the economic burden of Pompe disease and the health economic value of its trea...
A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers [0.03%]
加拿大专利药品价格审查委员会(PMPRB)、公共和私人付费者之间的药物预算影响分析(BIA)建议比较
Naghmeh Foroutan,Jean-Eric Tarride,Feng Xie et al.
Naghmeh Foroutan et al.
The Canadian budget impact analysis (BIA) guidelines were published by the Patented Medicine Prices Review Board (PMPRB) in 2007. Some Canadian federal, provincial and territorial (F/P/T) drug plans have updated their BIA guidelines since t...
The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta [0.03%]
艾伯塔省行业资助的医疗器械临床试验的成本
Ilke Akpinar,Arto Ohinmaa,Lars Thording et al.
Ilke Akpinar et al.
Objective: Our objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada. Methods: ...
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK [0.03%]
英国绝经后激素受体阳性晚期乳腺癌初始内分泌治疗女性使用氟维司群500毫克的的成本效益分析
Claire Telford,Evelina Bertranou,Samuel Large et al.
Claire Telford et al.
Introduction: The selective estrogen receptor degrader fulvestrant is approved for the first-line treatment of postmenopausal patients with hormone receptor-positive (HR+), locally advanced or metastatic breast cancer who...
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review [0.03%]
一项系统性综述：未接受透析CKD患者贫血相关治疗的经济负担及与健康有关的生活质量
Pablo E Pergola,Roberto Pecoits-Filho,Wolfgang C Winkelmayer et al.
Pablo E Pergola et al.
Background: The cost and health-related quality of life (HRQoL) burden associated with treatments for anaemia of chronic kidney disease (CKD) is not well characterized among non-dialysis-dependent (NDD) patients. ...
Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM) [0.03%]
法国洛匹那韦/利托那韦单药治疗与标准抗逆转录病毒联合治疗抑制人类免疫缺陷病毒型1的成本效益分析（ANRS 140 DREAM研究）
Osvaldo Ulises Garay,Marie Libérée Nishimwe,Marwân-Al-Qays Bousmah et al.
Osvaldo Ulises Garay et al.
Background: Protease inhibitor monotherapy is a simplified treatment strategy for virally suppressed HIV-positive patients that has the potential for cost savings, as fewer drugs are used than with combination therapy. Ho...